| Project/Area Number |
26670377
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | インビボイメージング / 幹細胞 / 大腸がん / EGFファミリー / EGF受容体 / 体外イメージング / ＥＧＦ |
|---|
| Outline of Final Research Achievements |
Epiregulin (EPR) is a member of EGF family ligands and exert numerous cellular functions including stem cell stimulation. EPR is synthesized as a membrane-anchored protein (pro-EPR) and then proteolytically cleaved to yield a soluble form of EPR. While it is expressed at relatively low levels in most adult tissues, EPR is overexpressed in human colon, breast, and other cancers. We developed several anti-EPR monoclonal antibodies that specifically recognize human EPR, but not other EGF family ligands. Anti-EPR antibody is internalized into epiregulin expressing cancer cells. Using this system, we developed a mouse in vivo imaging system for epiregulin producing tumor. Our results suggest that anti-EPR antibodies represent valuable tools for medical imaging and for delivering agents for the treatment of cancers
|
